Institute of Immunology, Zhejiang University School of Medicine, Hangzhou, 310058, China.
The Key Laboratory for Immunity and Inflammatory Diseases of Zhejiang Province, Hangzhou, 310058, China.
Adv Biol (Weinh). 2021 Mar;5(3):e1900311. doi: 10.1002/adbi.201900311. Epub 2021 Feb 11.
Cancer is the outcome of the conflict between the host immune system and cancer cells. The crosstalk between immune cells and tumor cells within the tumor microenvironment (TME) influences tumor progression and metastasis. Many studies have clarified the cellular and molecular events that can induce cancer cells to escape immune surveillance, including those involving tumor-induced myeloid cell-mediated immunosuppression. Emerging evidence indicates that tumor-infiltrating myeloid cells (TIMs) accelerate tumor growth and induce angiogenesis, metastasis, and therapy resistance once converted into potent immunosuppressive cells. Here, how tumor infiltrating myeloid cells participate in tumor immune evasion and the prospects of these cells in cancer immunotherapy are discussed.
癌症是宿主免疫系统和癌细胞之间冲突的结果。肿瘤微环境（TME）中免疫细胞与肿瘤细胞之间的串扰影响肿瘤的进展和转移。许多研究阐明了可诱导癌细胞逃避免疫监视的细胞和分子事件，包括涉及肿瘤诱导的髓样细胞介导的免疫抑制的事件。新出现的证据表明，肿瘤浸润髓样细胞（TIMs）一旦转化为强效免疫抑制细胞，就会加速肿瘤生长并诱导血管生成、转移和治疗耐药性。本文讨论了肿瘤浸润髓样细胞如何参与肿瘤免疫逃逸以及这些细胞在癌症免疫治疗中的前景。
